[HTML][HTML] Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results
For patients with chronic myeloid leukemia in chronic phase (CMLCP), treatment with a BCR-
ABL1 tyrosine kinase inhibitor (TKI), such as imatinib or nilotinib, can result in high response …
ABL1 tyrosine kinase inhibitor (TKI), such as imatinib or nilotinib, can result in high response …
Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results
TP Hughes, B Leber, F Cervantes, N Spector… - Leukemia, 2017 - go.gale.com
For patients with chronic myeloid leukemia in chronic phase (CML-CP), treatment with a
BCR-ABL1 tyrosine kinase inhibitor (TKI), such as imatinib or nilotinib, can result in high …
BCR-ABL1 tyrosine kinase inhibitor (TKI), such as imatinib or nilotinib, can result in high …
Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results.
TP Hughes, B Leber, F Cervantes, N Spector… - Leukemia, 2017 - europepmc.org
For patients with chronic myeloid leukemia in chronic phase (CML-CP), treatment with a
BCR-ABL1 tyrosine kinase inhibitor (TKI), such as imatinib or nilotinib, can result in high …
BCR-ABL1 tyrosine kinase inhibitor (TKI), such as imatinib or nilotinib, can result in high …
Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results
TP Hughes, B Leber, F Cervantes, N Spector… - …, 2017 - pubmed.ncbi.nlm.nih.gov
Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1
on imatinib: final ENESTcmr randomized trial results Sustained deep molecular responses in …
on imatinib: final ENESTcmr randomized trial results Sustained deep molecular responses in …
[HTML][HTML] Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results
TP Hughes, B Leber, F Cervantes, N Spector… - Leukemia, 2017 - ncbi.nlm.nih.gov
For patients with chronic myeloid leukemia in chronic phase (CMLCP), treatment with a BCR-
ABL1 tyrosine kinase inhibitor (TKI), such as imatinib or nilotinib, can result in high response …
ABL1 tyrosine kinase inhibitor (TKI), such as imatinib or nilotinib, can result in high response …
[引用][C] Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results
TP Hughes, B Leber, F Cervantes, N Spector… - …, 2017 - research.sahmri.org.au
Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1
on imatinib: final ENESTcmr randomized trial results — SAHMRI Skip to main navigation …
on imatinib: final ENESTcmr randomized trial results — SAHMRI Skip to main navigation …
[引用][C] Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results
TP HUGHES, B LEBER, F CERVANTES, N SPECTOR… - 2017 - observatorio.fm.usp.br
[引用][C] Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results
TP Hughes, B Leber, F Cervantes, N Spector… - Leukemia, 2017 - cir.nii.ac.jp
Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1
on imatinib: final ENESTcmr randomized trial results | CiNii Research CiNii 国立情報学 …
on imatinib: final ENESTcmr randomized trial results | CiNii Research CiNii 国立情報学 …
[引用][C] Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results
TP HUGHES, B LEBER, F CERVANTES… - …, 2017 - observatorio.fm.usp.br
Authors: HUGHES, TP; LEBER, B.; CERVANTES, F.; SPECTOR, N.; PASQUINI, R.;
CLEMENTINO, NCD; SCHWARER, AP; DORLHIAC-LLACER, PE; MAHON, FX; REA, D.; …
CLEMENTINO, NCD; SCHWARER, AP; DORLHIAC-LLACER, PE; MAHON, FX; REA, D.; …
Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results.
TP Hughes, B Leber, F Cervantes, N Spector… - Leukemia, 2017 - europepmc.org
For patients with chronic myeloid leukemia in chronic phase (CMLCP), treatment with a BCR-
ABL1 tyrosine kinase inhibitor (TKI), such as imatinib or nilotinib, can result in high response …
ABL1 tyrosine kinase inhibitor (TKI), such as imatinib or nilotinib, can result in high response …